The difference between information and
expert, data-driven actionable intelligence
| November 2016 |
Welcome to the November 2016 issue of CMC Market Outlook
This monthly e-newsletter provides valuable insights for both buyers and sellers of CMC drug development services. Our coverage will help you identify and understand market trends that will inform your strategic business perspective.
Enjoy the November issue!
Trial Registrations Reflect Improved Funding
The impact of the strong funding environment for emerging bio/pharma companies is being reflected in new clinical trial starts. An analysis of new clinical trial registrations in the clinicaltrials.gov database indicates that Phase I and II trial starts for which an emerging bio/pharma company is the sponsor or principal collaborator were up 65% in the first half of 2012 versus the first half of 2016.
The jump in trial registrations is closely correlated to the improved funding environment that emerging bio/pharma companies have enjoyed in recent years. External funding for emerging biopharma companies in 2015, i.e., the funding year immediately preceding the 2016 trial registrations, was more than… read on
Five Themes That Will Drive the CMO Industry
by Jim Miller, President
Trade shows provide a good opportunity to gauge the temperature of the contract development and manufacturing organization (CDMO) industry and find out which trends and concerns are most on people’s minds. Five themes really stood out from conversations at the CPhI Worldwide event held in Barcelona in October 2016.
Mergers and acquisitions continue to create the most buzz around the industry, and speculating about which contract manufacturing organizations (CMOs) are the next target or the next acquirer is a favorite topic of conversation. The industry certainly seems set up for… read on
How big is the market for…?
This is a handy guide to frequently requested data about the bio/pharma contract services industry.
The market for overall bio/pharmaceutical outsourced development spending:
| Market Growth | Source |
| 2016: $26 billion 2019: $31 billion |
Medpace Presentation at Baird Global Healthcare Conference September 2016 |
Read more about the size of the contract services market for various segments.
Bio/Pharma Sponsor Spending on In-house Manufacturing Capacity Soars
| This data-rich report, Bio/Pharma CapEx Trends 2016, identifies 3 indicators of what’s ahead for your business:
1. Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry. 2. Bio/pharma companies have invested over $150 billion for new plant and equipment in the past 5 years. 3. Based on recent capital expenditure trends, learn why bio/pharma companies would rather “make than buy.”  |
 |
PharmSource Strategic Advantage
PharmSource’s STRATEGIC ADVANTAGE service is the industry’s most respected outsourcing information web portal for serious consumers of information on contract drug development and manufacturing. Developed from PharmSource’s expert proprietary research, you won’t find this information in any other resource.
See for yourself how this resource gives you vital tools for understanding the industry.
To request a test-drive today, contact Nathaniel Celentano at nathaniel@pharmsource.com / +1-703-383-4903, ext. 112 (ET USA).